> *Nature, like a Sphinx, And the temptation of humans with Her mysteries is stronger Considering that maybe there are no mysteries at all*.
>
> ---F.I. Tyutchev

Introduction
============

Carnosine (β-alanyl-[l]{.smallcaps}-histidine) was discovered and its structure determined in the very beginning of the 20th century.[@b1-cia-4-031] It was the first and the simplest example of biologically active peptides (actually a dipeptide), opening the long list of widespread natural protein and peptide regulators of metabolism. The biological role of carnosine is illustrated by a clear correlation between its concentration and the functional activity of muscles, by the period of its accumulation related to a specific step of ontogeny, and by the presence of special enzymes providing synthesis and metabolic transformation of carnosine. Recently we have originally discovered that some natural compounds of a peptide character or their metal chelates may be among the most potent lipoperoxidase mimetics that have ever been characterized.[@b2-cia-4-031] [l]{.smallcaps}-carnosine and its ophthalmic prodrug bioactivating *N*-acetylcarnosine (NAC) are part of this group of products.[@b3-cia-4-031] NAC, like its parent compound, carnosine, occurs naturally throughout the human body. Both compounds are found primarily in the heart and skeletal muscles and in the brain. However, we have found appreciable levels of [l]{.smallcaps}-carnosine in transparent human lenses which are markedly depleted in mature cataracts.[@b4-cia-4-031] The concentration of carnosine in transparent crystalline lenses detected was about 25 μM. At different stages of cataract development, the level of carnosine fell, reaching about 5 μM.1 Research with NAC demonstrates that it is effective not only in preventing cataracts but also in treating them. NAC has been shown to improve vision by partially reversing the development of the cataract, thus increasing the transmissivity of the lens to light.[@b5-cia-4-031]

One of the obscure aspects of the carnosine problem is the biological significance of the enzymatic metabolism of carnosine or its derivatives in tissues. Thus, in order to change an antioxidant status, tissue enzymes can modify the NAC molecule and deacetylation will increase in vivo the resistance of lens tissues and its cells to oxidative stress. This modification of NAC may serve as a regulator of reactive oxygen species level in the ocular biological tissues and fluids. The topical administration of NAC as a universal bioactivating antioxidant for vision in the developed and patented lubricant eye drop formulations delivers pure [l]{.smallcaps}-carnosine and allows its increased intraocular absorption into the aqueous humor surrounding the lens, thus enabling significant improvements in anticataract drug efficacy and the minimization of side-effect from either local or systemic drug absorption/bioavailability to the eye, and also creates optimization effects in the number of ocular degenerative age-dependent disorders.[@b5-cia-4-031]

The research and development team at Innovative Vision Products, Inc. (IVP; County of New Castle, DE USA) studied the effects of lubricant eye drops designed as 1% NAC prodrug of [l]{.smallcaps}-carnosine containing a mucoadhesive cellulose-based compound combined with corneal absorption promoters in a drug delivery system. The predicted responses of the corneal and conjunctival penetrations to the synergistic promoters are useful in controlling the extent and pathway of the ocular and systemic absorptions of instilled NAC prodrug in designed ophthalmic formulations thereof.[@b5-cia-4-031] The developed by IVP NAC prodrug and codrug lubricating eye drop systems (including principal regulatory registered eye drops design Clarastill^™^ and Can-C^™^ lubricating eye drops) have been marketed under numerous brand labels. Several expert antiaging companies are supplying the eye health comfort NAC drops on the market today with more than 5 years of experience and consequently, there exists empirically successful reasoning that NAC lubricant eye drops are reputed to cure cataracts and other eye diseases.

The risk, cost and social requirement factors drive the investigation of pharmaceutical approaches to the management of cataracts. More than 17 million people are blind because of cataract and 28,000 new cases are reported daily worldwide.[@b6-cia-4-031] In the United States, over 1.3 million cataract operations are performed annually at a cost of \$3.5 billion.[@b7-cia-4-031] Forty-three percent of all visits to ophthalmologists by Medicare patients are associated with cataract.[@b7-cia-4-031] Approximately 25% of the population over 65 and about 50% over 80 have serious loss of vision because of cataract. Since the population over 55 is most susceptible to lens opacification and is expected to increase 4-fold worldwide and significantly in the United States,[@b8-cia-4-031] cataract is a major disease both in terms of numbers of people involved and in economic impact.

The importance of quality of vision (QOV) along with quality of life (QOL) in antiaging medicine has been recently widely recognized. We have conducted studies to quantitatively analyze factors related to QOV using the Halometer DG (Disability Glare) tester, a clinically developed ophthalmic diagnostic instrument.[@b9-cia-4-031] Glare is broadly defined as representing those effects of light that impair visual efficiency. The physical mechanisms and physiological causes of glare in human vision are reported.[@b9-cia-4-031] These mechanisms are scattering in the cornea, lens, and retina, and diffraction in the coherent cell structures on the outer radial areas of the lens. This scattering and diffraction are responsible for the "bloom" and "flare lines" seen around very bright objects. The diffraction effects cause the "lenticular halo". The quantitative assessment of these glare effects was reported by our group, and an algorithm for using these clinical characteristics of vision to add glare effects to digital lens images in age-related human cataracts was presented.[@b9-cia-4-031]--[@b12-cia-4-031] Disability glare (DG) results when a light source reflects from or otherwise covers the visual task, like a veil, obscuring the visual target, reducing its contrast and making the viewer less able to see and discriminate what is being viewed. The problem is illustrated in [Figure 1](#f1-cia-4-031){ref-type="fig"}.

In this paper, the CIE term, DG is used to represent retinal exposure from a glare source that results in diffused intraocular light scattering within the ocular media. This diffused light induces an unwanted optical veil of luminance that reduces contrast and target visibility. Currently, there are no good instruments for measuring DG, and there is no good "metric" for quantifying DG. Despite the fact that several tests designed to "penetrate" lens opacification in order to assess visual function at the retinal-neural level are in use clinically, each has rather severe limitations, particularly in cases where the need for clear definition of functional integrity is greatest. For patients with cataract, visual function in everyday conditions is poorly predicted by classical Snellen acuity, grating acuity, and grating contrast sensitivity when test measurements are made under "minimal-glare" conditions.[@b13-cia-4-031] This statement was supported by the Committee on Ophthalmic Procedures Assessment of the American Academy of Ophthalmology on contrast sensitivity and glare testing in the evaluation of anterior segment disease.[@b14-cia-4-031] It's believed that DG assessment should become an integral part of eye exams for people over 50 years of age. We have recently designed an innovative Halometer DG tester ([Figure 2A--E](#f2-cia-4-031){ref-type="fig"}) that overcomes previous deficiencies.[@b9-cia-4-031]--[@b12-cia-4-031] IVP patented the original Halometer DG concept and designed the vision diagnostic device for commercial implementation.[@b9-cia-4-031]--[@b12-cia-4-031] The Halometer DG tester is vital for aging drivers with poor vision resulting from aging, cataract, and ocular disease(s). Glare testing provides secondary information concerning cognitive and physical performance. The Halometer DG is sensitive even to mild impairments. Such information is often ignored or denied until it is advanced with marked functional impairment resulting in a serious accident. Relationships between computer task performance (accuracy and speed) and visual function parameters (visual acuity, glare sensitivity, visual field, and color vision) are also important.[@b14-cia-4-031] Among this cohort of patients with age-related cataracts and ocular degenerative disorders, visual acuity, disability glare sensitivity, and color vision defects are significant predictors of computer task performance. Visual function parameters of the better eye usually plays a more significant role than parameters of the worse eye, and disability glare is the significant predictor of computer task accuracy.[@b14-cia-4-031] The symptoms include headaches, blurred distance vision, halos, double vision, and generally irritated and fatigued eyes ([Figure 2D--E](#f2-cia-4-031){ref-type="fig"}).

In the present clinical study we assessed vision before and after the 9-month term of topical ocular administration of NAC lubricant eye drops or placebo in 75 symptomatic patients with age-related uncomplicated cataracts in one or both eyes, with acuity in one eye of 20/40 or worse (best-corrected distance), and no previous cataract surgery in either eye and no other ocular abnormality and 72 noncataract subjects ranged in age from 54 to 78 years. Subjects in these subsample groups have reported complaints of glare and wanted to administer eye drops to get quick eye relief and quality of vision. Glare sensitivity was measured with the Halometer DG tester. Prior to treatment with NAC lubricant eye drops there was significant disability glare that was not correlated with acuity. The disability glare was especially manifested under nighttime conditions and expressed during a prolong work with a computer-controlled video display.

Following 9 months of treatment with NAC lubricant eye drops (Can-C^™^) ([Figure 3](#f3-cia-4-031){ref-type="fig"}, [Table 1](#t1-cia-4-031){ref-type="table"}), most patients' glare scores were improved or returned to normal in disability glare tests with Halometer DG. Improvement in disability glare was accompanied with independent improvement in acuity ([Table 5](#t5-cia-4-031){ref-type="table"}). Furthermore, patients with the poorest pretreatment vision were as likely to regain certain better visual function after 9 months of treatment with NAC lubricant eye drops as those with the better pretreatment vision.

NAC prodrug and codrug ophthalmic formulations are applied topically to the eye and moreover, its controlled time-released ophthalmic ingredient, [l]{.smallcaps}-carnosine, exerts antiglycation, bioactivating antioxidant properties in the lens and cornea as a scavenger of lipid peroxides, singlet oxygen, and OH·radicals and spatial aspects of intracellular pH regulation.[@b5-cia-4-031],[@b15-cia-4-031] In contrast to the possible pirated brands of NAC eye drops available on the market that employ D/L-isomeric forms of NAC, in the IVP conducted clinical studies only the natural [l]{.smallcaps}- isomeric form of NAC raw material was specifically synthesized at the cGMP facility and employed for the manufacturing of the Can-C^™^ eye drops.

In the initial stages and the planning of the present study, the enrolled patients suffered from different degrees of glare problems. The purpose of this study is to examine the effects of a most often recommended short-term 9-month treatment with 1% NAC in ophthalmic formulation with a lubricant, carboxymethylcellulose, on improvement of visual impairment and glare disability in older adult subjects and older patients with cataract whose occupations frequently involve driving or computer activities.

Strengths of this study design are the use of a comparison group of patients with cataract and older subjects (including drivers or computer users) who were treated with placebo (Control group) followed prospectively over the same time period and the statistical adjustment for potential differences in the treated with NAC groups that could serve as the indication for the hypothesized improvement effect on vision for better occupation returns. We used a randomized design that was ethical since *NAC* is an accepted and proven therapeutic modality of vision care available on the market of antiaging medicine since 2002.[@b10-cia-4-031],[@b15-cia-4-031]--[@b18-cia-4-031]

What we have found is there is currently a significant rise in the purchase orders that request a vendor/supplier to furnish the Can-C^™^ eye drops. We have first made a reference to electronic records of the product sales to patients who have been made the repurchase of the Can-C^™^ eye drops since December 2001. Based on this analysis, we record adjustments to inventory, making record sale during the continued repurchase program and analyze simultaneously the various parameters, including testimonials. With these figures, researchers judged on the patients' compliance rate to self-administer eye-drops.

Materials and methods
=====================

The first enrolled cohort of examined subjects consisted of 75 older adults with age-related uncomplicated cataracts in one or both eyes, and 72 adult subjects who did not have cataract in either eye. Patients in these subsamples suffered from different degrees of glare problems. Those with cataract ranged in age from 53 years to 83 years (mean ± SD, 69 ± 8 years), with 48% female, 100% white and of non-Hispanic origin. The noncataract subjects ranged in age from 54 to 78 years (mean ± SD, 66 ± 8 years); 53% were female, with 100% being white. Subjects who were cataract free had to meet the same inclusion criteria as the subjects with cataract described previously.[@b9-cia-4-031],[@b10-cia-4-031],[@b16-cia-4-031]--[@b18-cia-4-031] All subjects with cataract were required to meet the following inclusion criteria: (1) cataract in one or both eyes with best-corrected visual acuity of 20/40 or worse in one or both eyes as indicated by the medical record; (2) no previous cataract surgery in either eye; (3) a primary diagnosis of cataract in the medical record; (4) living independently in the community; specific items were needed to be addressed if appropriate; (5) driving skills: legally licensed to drive and drove during the 5 years prior to enrollment; (6) related general or eye health problems experienced during computer use: this was assessed by asking subjects if they have any symptom problems in the specific areas listed in [Table 2](#t2-cia-4-031){ref-type="table"}, [Figure 2D](#f2-cia-4-031){ref-type="fig"}. Among participants, bilateral cataracts were present in 95% of subjects according to the medical record from the most recent eye examination (within 1 month of enrolment). In the right eye, 46% had nuclear sclerotic cataract, 8% had cortical cataract, 9% had posterior subcapsular cataract, and 38% had a combination of at least two types. The breakdown was similar in the left eye, with 49% nuclear sclerotic, 10% cortical, 7% posterior subcapsular, and 35% combination. Seventy-four percent of subjects with cataract had no additional ocular conditions other than refractive error; 6% had early nonexudative age-related maculopathy, 9% had primary open-angle glaucoma (POAG) associated with cataract, 3% had diabetic retinopathy, 1% had a combination of two of these problems, and 7% had another ocular condition. Subjects who were cataract-free had to meet the same inclusion criteria as the subjects with cataract, except that they were required to be free of cataract and to have a best-corrected visual acuity of 20/25 in each eye, according to medical record review. No cataract-free subjects had secondary eye conditions other than refractive error.

Patients with known or presumed hypersensitivity to any component of the ophthalmic preparations (active substances or excipients), and those treated with drugs that could interfere with this trial, were also excluded from the study. The subjects were recruited and examined by IVP ophthalmology practices. The study protocol was approved by the corporative review board for human use. After the purpose of the study had been explained, each subject was asked to sign a document of informed consent before enrolling. Demographic data, driving status during the prior 5 years and computer use at work were confirmed by interview ([Table 3](#t3-cia-4-031){ref-type="table"}).

Procedures
----------

After enrolment, subjects were computer-randomized into two groups assigned according to the double blind method: to receive treatment with NAC 1% eye drops (Can-C^™^), or to a control group who received placebo eye drops. The blinded testing was carried out by an independent medical worker who handed out the NAC versus placebo eye drops (control group) to the randomized subject members of the clinical groups. The enrolled subjects underwent follow-up examinations at baseline and after 9 months of enrolment. Test examiners were masked to the driving histories of all subjects. Two types of visual functions were assessed: visual acuity and glare sensitivity (DG). All acuity measurements were made while subjects wore the lens correction they typically used during the performance of everyday distance activities, including driving. Each eye was assessed separately. Distance acuity was measured as described before using the letter chart and its standard protocol, and was expressed as log minimum angle resolvable.[@b9-cia-4-031],[@b10-cia-4-031],[@b16-cia-4-031]--[@b20-cia-4-031] For each eye, visual acuity measurements were grouped into four categories: 20/25 or better, 20/25--20/30, 20/35--20/50, and worse than 20/50. These cut-off points were chosen because they were the approximate quartiles of the acuity distribution and included the practically significant cut-off point for driving licensure in many countries (20/40 to 20/50). Some of the vision problems from this course will include computer-related work and the circumstances under which that work is performed.

Slit-lamp biomicroscopic examination or exampled photographic registration was performed after pupil dilation to a minimum of 6 mm with tropicamide.

DG was defined with an optical instrument and method for measuring susceptibility to glare of a human vision system as described[@b9-cia-4-031]--[@b12-cia-4-031],[@b16-cia-4-031]--[@b18-cia-4-031] and schematically presented in [Figures 2A](#f2-cia-4-031){ref-type="fig"}--C. A constant "point"-like bright glare source is used to create the glare condition ([Figure 2C](#f2-cia-4-031){ref-type="fig"}). The examining room was dark (less than 20 foot-candles) as typical when working with the glare testers to assure maximum contrast of the projected target. Tests were performed with the best correction in place. The indicator of optotypes on the front or back panels of the instrument indicated the tested optotype to the patient or clinician, respectively. The diagnostic block of a device contained source light window (glare source) and the moving indicator of the optotypes illuminated with red or green light ([Figure 2A, C](#f2-cia-4-031){ref-type="fig"}). The back panel of the Halometer device facing the clinician was equipped with a chart/scale and with a moving indicator of the optotype transition. According to a special embodiment of the invention,[@b9-cia-4-031]--[@b12-cia-4-031],[@b16-cia-4-031]--[@b18-cia-4-031] for the clinical testing of glare sensitivity of a patient we used an illuminated target with red or green color, which enables the assessment of the effect of wavelength on the scattered light.

Treatments with NAC 1% lubricant eye drops
------------------------------------------

NAC eye drops (Can-C^™^) contained a 1% solution of NAC[@b21-cia-4-031]--[@b23-cia-4-031] with a lubricant, 0.3% carboxymethylcellulose, in the isotonic ophthalmic formulation in borate buffer with preservative benzyl alcohol (corneal absorption promoter) and showed the increased intraocular absorption of the active principle ([l]{.smallcaps}-carnosine) in the aqueous humor compared to topical administration of a pure 1% NAC solution: Deionized water970 gGlycerine, 1.0%13 g*N*-Acetylcarnosine, 1.0%10 gCarboxymethylcellulose, 0.3%3 gBenzyl alcohol, 0.3%3 gPotassium borate7.91 g[\*](#fn1-cia-4-031){ref-type="fn"}Potassium bicarbonate3.47 g[\*](#fn1-cia-4-031){ref-type="fn"}

The ophthalmic formulation thus creates a facility to examine the efficacy of treatment for improvements of vision during the short-term periods of administration of NAC 1% eye drops (9 months in the present study).The administration schedule was two drops instilled twice daily, for patients assigned to NAC and those assigned to placebo (the same formulation without NAC, 1%) alone for 9 months. The use of other topical or nutritional antioxidants was not measured or evaluated between the two groups. The control groups and the treated group did not take any prescribed antioxidant vitamins that might have added to the antioxidant level. Neither the investigators nor the patients knew who was receiving NAC.

Statistical analyses
--------------------

Statistical analysis was performed by Student's *t* test; *p* = 0.05 was taken as the upper limit of significance. To assess associations, correlation and linear regression analyses were used.

Repurchase earnings analysis
----------------------------

The major factors that led to the sharp increase in net earnings for the quarters of 2007 compared to the corresponding quarters of 2003 were a significant increase in selling, general and administrative expenses for the promotion of Can-C^™^ NAC lubricant eye drops to public. The launch of Can-C^™^ ophthalmic formulation and continuing strong sales as the anticataract and antiglare product contributed most of the sales growth in the USA and Europe. The Computer-Based Facilities Inventory and Utilization Management Information Subsystem allowed authors to analyze the trades that occurred and ongoing from the fourth quarter of 2002 till the third quarter of 2007 and now they have in place a publicly-announced repurchase program that, after calculation of the number of sold eye drops, generally supports the enhanced patient's compliance and improved safety of the drug candidate in subjects who may self-administer the prescribed by IVP medication (NAC lubricant eye drops) for the reduction or treatment of cataracts, and every challenge opportunity is taken to promote self-care.

Patient compliance in both groups described in this study to self-administer NAC lubricant eye drops (Can-C^™^) was considered excellent.

Results
=======

Sample characteristics
----------------------

[Table 3](#t3-cia-4-031){ref-type="table"} lists the demographic and ergonomic occupational characteristics of the cataract (n = 75) and noncataract groups (n = 72). Those with cataract were similarly older on average with the noncataract group of subjects. Both groups were split evenly between males and females, and had similar racial composition in a totally white population.

[Table 4](#t4-cia-4-031){ref-type="table"} lists the visual function for both groups enrolled in the study and the distribution of visual acuity and disability glare scores for subjects with cataract and those without. As would be expected by the case definition for cataract group membership, those in the cataract group had impairments in visual function as compared to the no-cataract group. This was true for both the "worse" and better" eyes. In addition, visual acuity in the range of 20/35 to 20/50 and disability glare readings in the range of glare radius more than 12 mm was associated with driving difficulties (such as crash involvement) and computer-related injuries ([Table 2](#t2-cia-4-031){ref-type="table"}). Although not statistically significant, there was also a possible relationship between visual acuity worse than 20/50 and crashing during driving experience.[@b24-cia-4-031] DG (glare radius measured in millimeters) was correlated for statistical significance with visual acuity at red and green targets at baseline and 9-month examination interval in the total samples of older subjects with cataract and noncataract older adult subjects ([Table 5](#t5-cia-4-031){ref-type="table"}).

Older subjects enrolled in the study were divided into two groups: treated with NAC and control group ([Tables 6](#t6-cia-4-031){ref-type="table"} and [7](#t7-cia-4-031){ref-type="table"}). [Table 6](#t6-cia-4-031){ref-type="table"} lists the analogous and adjusted analyses for the worse eye, which generated results in the eyes with cataract upon treatment with NAC prodrug ophthalmic formulation are qualitatively similar to those for the better eye. None of the baseline differences between the different groups was significant. The two groups were similar in smoking history, sunlight exposure, and alcohol use. There was no substantial difference in the use of sunglasses, where the patients lived, or occupational hazard exposure between the two groups.

Ophthalmic examinations indicated that the methodological variances of measurements were approximately equal. Correlations of glare sensitivity at red versus green targets were significant ([Table 5](#t5-cia-4-031){ref-type="table"}). Intraoperator correlation coefficients obtained as repeated measurements for each combination of operator, eye (right or left), and glare radius (at red and green targets) were statistically significant and presented earlier.[@b9-cia-4-031],[@b10-cia-4-031],[@b16-cia-4-031]--[@b18-cia-4-031] Overall, the reproducibility for the one operator was good. [Tables 4](#t4-cia-4-031){ref-type="table"}--[8](#t8-cia-4-031){ref-type="table"} summarize the effects of study treatment on visual acuity and glare sensitivity over 9 months in older subjects with cataract and no cataract. In the control placebo-treated group, comparison with baseline values showed some variability of data in gradual worsening of glare sensitivity at red and green targets and minimal visual acuity changes over 9 months ([Table 7](#t7-cia-4-031){ref-type="table"}). Glare sensitivity indicated mostly changes in lens clarity and confirmed the tiny changes in the optical media of the eye at the short-term follow up examinations when slit lamp associated image analysis data and densitometric readings did not differ significantly with baseline.[@b9-cia-4-031],[@b10-cia-4-031],[@b16-cia-4-031]--[@b18-cia-4-031]

In the NAC-treated group, 9-month follow-up generally showed an improvement in visual acuity (according to the distribution score of distance acuities in worse and better eyes) and a significant improvement in glare sensitivity at red and green targets was documented in worse and better eyes using a critical cut point halometer score ([Tables 6](#t6-cia-4-031){ref-type="table"}, [8](#t8-cia-4-031){ref-type="table"}). Visual acuity was mostly improved in older subjects with cataract in a worse and better eyes and an improvement in glare sensitivity was found both in older subjects with cataract and noncataract older adult subjects in worth and better eyes after 9 months of treatment with NAC. The exampled images of cataract reversal in older subjects are presented on the slit lamp images just for note (see [Figure 4](#f4-cia-4-031){ref-type="fig"}).

The NAC-treated eyes had statistically significant difference in VA, glare sensitivity compared with the control group (*p* \< 0.001) at 9-month time point of treatment, as supported by the overall *t*-test results of the ratio of the follow-up data to the baseline values ([Table 8](#t8-cia-4-031){ref-type="table"}). The previously published data illustrate examinations over 24 months of the eyes that were treated with NAC to show that the effect of treatment is sustainable over more prolonged periods.[@b10-cia-4-031],[@b16-cia-4-031]--[@b18-cia-4-031] In the eyes of older subjects with different localization and grade of cataract and in noncataract older adult subjects, short-term and prolonged treatment with NAC did not seem to result in a worsening of the visual outcome in this study and elsewhere.[@b10-cia-4-031],[@b16-cia-4-031]--[@b18-cia-4-031] Topical short- or long-term administration of 1% NAC to the eye was very well tolerated, with no ocular or systemic adverse effects, no hyperemia of conjunctival vessels, and no signs of allergy or other toxic manifestations being reported. No clinically significant changes from baseline, and no statistically significant differences between the treatment and control groups, were observed regarding ocular comfort and ocular signs and symptoms (lack of burning and stinging, blurred vision, ocular dryness, superficial punctate keratitis, foreign body sensation, itching, ocular discharge, ocular pain, tearing, ocular inflammation, photophobia). All patients completed the study without any problems related to their allocated treatment.

The board of directors analyzed the repurchase behavior of Can-C^™^ in open market programs. The product has been on the market since November, 2001 and it is well known according to the records how many boxes of Can-C^™^ are actually repurchased. The analyses in this paper demonstrate the repurchase behavior of patients in more than 50,000 individual buyback programs. We find that repurchase announcements during 5 recent years of follow-up give the credible figure of 50,000 patients who are compliant users of Can-C^™^ eye drops for published therapeutic indications (including treatment of cataracts) and demonstrate the safety of all-in-one eye drops on a daily basis. On average, these patients repurchase more boxes of the drug than they originally authorized over the last four quarters following the announcement of greater sales, though there is considerable variation across patients' requests. We examine the factors influencing repurchase behavior, and find that repurchases in the latest quarters are associated with a number of variables, including the efficacy of the product and its persistent safety to control the signs of glare sensitivity, cataract amelioration, and quality of vision during daily life activities. We also consider the past and current returns, profitability, and prior repurchase activity.

According to the records of repurchase behavior, the unique and patented NAC lubricant all-in-one eye drops formula Can-C^™^ can also provide beneficial results with the following eye-disorders: Presbyopia.[@b15-cia-4-031],[@b23-cia-4-031]Open-angle primary glaucoma (in combination with beta-blockers).Corneal disorders.Computer vision syndrome.Eyestrain.Ocular inflammation.Blurred vision.Dry eye syndrome.Retinal diseases.Vitreous opacities and lesions.Complications of diabetes mellitus and other systemic diseases.Contact lens difficulties, particularly with soft contact lenses. (Not only do the lubricants in the Can-C^™^ NAC eye-drop help to make contact lenses more comfortable, but NAC is also believed to reduce the build up of lactic acid in the eye, thus enabling the lens to be left safely in the eye for longer).

We also investigate how sales outstanding change following repurchase program announcements. Over the test last year period the average increase in sales is about 80% and only about 35% of the number is repurchased. For the most part, changes in sales of Can-C^™^ are influenced by the same factors affecting repurchases and in the predicted direction of warranted efficacy and safety of the product. [Table 9](#t9-cia-4-031){ref-type="table"} is presenting the exampled but most typical and standard testimonials received from patients who have purchased originally Can-C^™^. The NAC lubricant eye drops have been successfully used for medically oriented home health care usually helping seniors recover or exercise with aid in recovery from visual impairment or illness including cataracts ([Figure 5](#f5-cia-4-031){ref-type="fig"}). Medically oriented home-health care represents less than half of formal home-health services rendered to the long-term-care population. It is important to note that most work for home health agencies, hospitals, or public health departments are licensed by the state.

Discussion
==========

It is foreseen that the health problems of the elderly are multiplying exponentially with the demographic changes in our aging population. Visual impairment represents one of the most significant of these problems, not only in terms of eye diseases, but because of the associated dangers affecting the rest of the body.[@b25-cia-4-031]

The four most prevalent age-related ocular diseases are macular degeneration, open-angle glaucoma, cataract, and diabetic retinopathy.[@b26-cia-4-031],[@b27-cia-4-031] Normal visual changes that occur with aging include presbyopia, decreased contrast sensitivity, decreased dark/light adaptation, and delayed glare recovery.[@b28-cia-4-031] This decline in vision is associated in part with an increase in vehicular accidents per mile driven by the elderly.[@b29-cia-4-031] The visually demanding computer task had a more pronounced effect on the elderly than on the young. In this study, we examined the visual function and glare disability of older subjects without cataract and in the presence of cataract as a patients' perception of their daily living ability to perform vision dependent tasks. The traditional clinical measurement of vision, Snellen letter visual acuity, can provide an inadequate measure of forward light scatter relevant to glare effects in adult subjects.[@b30-cia-4-031],[@b31-cia-4-031] To determine whether glare sensitivity (halos) was significantly responsible for the change in visual functions in older subjects with cataract, we proposed a new halometer process, which is a form of disability glare test. In a previous study,[@b9-cia-4-031] we indicated that a set of halometric examination data at red and green targets would indicate that the condition of optical changes (improvement or deterioration) is related rather to the lens than the cornea. The visual and glare testing for both the better and worse eyes can give the results in the reference task for computer works and prognosticate impairments which significantly affect driving performance for any of the driving tasks (eg, the effects of cataracts, binocular visual field restriction, monocular vision).

We evaluated NAC 1% eye drops in the short-term 9-month therapy of cataracts and for improvement of visual functions in older subjects with no cataract. The NAC 1% eyedrops seem to improve the vision of the older adult subjects regardless of whether they have cataracts or not, but the improvement of visual acuity was significantly better in the group of cataract subjects versus the older adult subjects in the noncataract matched older adult group. This is an additional mode of evidence suggesting that carnosine applied in the form of NAC reverses lens opacity in humans \[[@b5-cia-4-031],[@b10-cia-4-031], [@b16-cia-4-031]--[@b18-cia-4-031], [@b21-cia-4-031]--[@b23-cia-4-031]\]. Utilizing the specific purity NAC ingredient manufactured at the cGMP facility according to specification developed by IVP ([Table 1](#t1-cia-4-031){ref-type="table"}), as a source of pharmacological principal [l]{.smallcaps}-carnosine, we have created the ophthalmic sustained drug delivery formulation ([Figure 3](#f3-cia-4-031){ref-type="fig"}), which contains varying amounts of the actives tailoring the enhanced intraocular absorption of the beneficial ingredient, naturally occurring dipeptide [l]{.smallcaps}-carnosine, to optimize its specific effect and purpose in producing the basic bioactivating antioxidant activity in vivo and reducing toxic effects of lipid peroxides to the crystalline lens. When cataract was accompanied with POAG, NAC was prescribed 15 min prior the topical application of beta-blocker, specifically used to decrease the intraocular pressure.[@b23-cia-4-031] The improvement of visual functions in patients with cataracts associated with POAG was accompanied with significant decrease of intraocular pressure and increase in the outflow facility in the eyes of patients with POAG treated with the indicated combined therapy.[@b23-cia-4-031] The treatment with NAC is improving eyesight in older adult cataract-free patients as intraocular released carnosine reacts with oxygen radicals, lipid peroxidation products, and carbohydrate oxidation products accumulated in the crystalline human lens with aging.[@b3-cia-4-031],[@b5-cia-4-031]

The entire body of supporting research on NAC and its bioactivated principle carnosine reveals its promise as a water-soluble universal antioxidant that works at several levels to defend against the oxidative stresses to the lens, glycosylation problems, and protect the lens proteins and the membrane lipids from oxidative damages thus preventing and reversing age-related cataracts in human eyes. Carnosine has been proposed to act as antioxidant *in vivo* and its activity in the crystalline lens can be related to the prevention of the free-radical-induced inactivation of activity of the proprietary antioxidant enzymes in the crystalline lens, such as Cu, Zn-superoxide dismutase (SOD). The protective effects of carnosine and related compounds against the oxidative damage of human SOD by peroxyl radicals generated from 2,2'-azobis(2-amidinopropane) dihydrochloride (AAPH) were established.[@b32-cia-4-031] Carnosine exhibits an ability to inhibit lipid peroxidation (LPO) catalysts besides inhibiting free metals, scavenging OH · and lipid peroxyl (RO2·) radicals or donating hydrogen ions. In addition to inhibiting the generation of lipid peroxyl radicals, carnosine catabolyzes lipid hydroperoxides to their alcohols both in aqueous medium and in a phospholipid system.[@b2-cia-4-031] A possibility exists from our studies that carnosine is reacting directly with MDA and other aldehydes/ketones. Indeed carnosine has been shown to protect against MDA-induced crosslinking and toxicity, and a hydroxynonenal-carnosine adduct has recently been characterized, providing further evidence for carnosine's potential as an aldehyde scavenger.[@b33-cia-4-031] The ability of [l]{.smallcaps}-carnosine to inhibit LPO reactions as well as to diminish the content of LPO products makes its ophthalmic prodrug NAC applied with lubricant carboxymethylcellulose a prominent tool in the therapy especially, of the posterior subcapsular and cortical cataracts, whose mechanism can be related with the toxic effects of LPO products.[@b34-cia-4-031]

In the cataractous lens, crosslinking of proteins by any means increases their effective molecular weight and produces light scattering and consequent lenticular opacity. The production of such high molecular weight protein complexes by disulphide bridges and covalent links with dialdehydes has been implicated in the formation of senile and other cataracts in humans. Both types of cross-linking may be caused by depletion of the lens' reduced glutathione and accumulation of LPO products in the lens tissue. The results of our studies strongly suggest that [l]{.smallcaps}-carnosine released from its ophthalmic prodrug NAC during its application to the eyes with cataracts is able to prevent the loss of reduced glutathione and to remove the secondary LPO products in biological systems. This, in turn, may lead to dissociation of the intermolecular protein cross-links due to glutathione-protein thiol-disulphide exchange mechanism and utilization of lipid peroxides and dialdehydes derived from LPO process, anchoring protein-lipid complexes in the lens.[@b35-cia-4-031] There is a rising evidence that carnosine prevents oxidation and glycation, both of which contribute to the crosslinking of proteins.[@b36-cia-4-031] The results suggest that histidine is the representative structure of [l]{.smallcaps}-carnosine for an anticrosslinking agent, containing the necessary functional groups for optimal protection against crosslinking agents. It has been proposed that the imidazolium group of histidine of carnosine may stabilize adducts formed at the primary amino group.[@b36-cia-4-031] Cellular aging is often associated with an increase in protein carbonyl groups arising from oxidation and glycation-related phenomena and suppressed proteasome activity. These "aged" polypeptides may either be degraded by 20S proteasomes or cross-link to form structures intractable to proteolysis and inhibitory to proteasome activity. For example, effects of [l]{.smallcaps}-carnosine on proteasome activity in the lens might explain the apparent decline in cataract, as proteasome activity is known to decline during lenticular ageing.[@b37-cia-4-031],[@b38-cia-4-031]

Protein glycation, which promotes aggregation, involves the unwanted reaction of carbohydrate oxidation products with proteins. Glycation of lens α-crystallin occurs *in vivo* and may contribute to cataractogenesis. Antiglycation compounds such as carnosine may be preventive, but interestingly carnosine reverses lens opacity in human trials. The mechanism for this observation may involve carnosine's ability to disaggregate glycated protein. Seidler and colleagues[@b39-cia-4-031] recently investigated this hypothesis using glycated α-crystallin as the *in vitro* model. The obtained in the present study data can be satisfactorily explained by the cited above ability of carnosine to protect cellular and tissue structures from aldehydes, which in excess may be toxic because of the nonenzymatic glycosylation of proteins. Glycation, preferentially modifies the ɛ-amino group of lysine residues in proteins, especially when proline neighbors lysine. It is likely that the structural similarity between lysyl-proline and β-alanyl-histidine allows carnosine to demonstrate its transglycation properties, eg to compete for the glycating agent, protecting proteins (lens crystallins) against modification.[@b40-cia-4-031] This cited core action of carnosine may totally protect lens tissue and cellular proteins from aldehydes, and this effect may be the main mechanism by which carnosine protects the crystalline lens against osmotic shock, oxidative stress, or toxic effects of several metabolites, including the eventual crosslinking of crystalline lens biomacromolecules with sugar(s)' metabolites and/or ascorbic acid oxidation byproducts. Actually, carnosine may prevent accumulation of Amadori products (forming after rearrangements of products of primary glycation) within lens cells and tissues as well as cross-linking of biomolecules.[@b40-cia-4-031] At moderately high concentrations, carnosine also reverses protein-aldehyde cross-linking, a reaction that is difficult to reverse, thus providing a rejuvenating effect on the lens for vision. Aggregation of crystallins, the lens proteins, is one of the basic stages of cataract formation. Among the protein aggregation models used to study the molecular mechanisms of the initial stages of lenticular opacity, UV-induced aggregation of β[l]{.smallcaps}-crystallin is most close to the *in vivo* conditions. Both carnosine and the carnosine derivative NAC have been shown to be effective in inhibiting the UV-induced aggregation of β[l]{.smallcaps}-crystallin at 20 mM concentration. The molecular chaperon-like properties similar to those of α-crystallin underlie the anticataract mechanism of action of carnosine and of the acetyl derivative of carnosine (prodrug).[@b5-cia-4-031]

Carnosine when present at surprisingly high levels (about 20 mM or over) can delay senescence of cells and reverse the senescent phenotype, restoring a more juvenile appearance. As better antioxidants/free-radical scavengers than carnosine do not demonstrate these antisenescent effects,[@b41-cia-4-031] additional properties of carnosine must contribute to its antisenescent activity. Having shown that carnosine can react with protein carbonyls, thereby generating "carnosinylated" polypeptides using model systems,[@b41-cia-4-031] it might be generally proposed that similar adducts can be generated in senescent cataractous lens fiber cells exposed to carnosine during the therapeutical treatments with 1% NAC lubricant eye drops *in vivo*.

These observations suggest that NAC may prevent and reverse cataracts. This therapeutic modality gives the most efficacious uptake of [l]{.smallcaps}-carnosine in the aqueous humor protecting carnosine from the short-term hydrolysis and this dipeptide is known to be an endogenous component in the mammalian and lens tissues.[@b23-cia-4-031] NAC was used as a prodrug of an antioxidant that is resistant to hydrolysis with human serum carnosinase.[@b3-cia-4-031] The [l]{.smallcaps}-carnosine liberated in aqueous humor can provide antioxidant protection in the areas around the lens, and penetrate and accumulate in the lens tissue.[@b3-cia-4-031]

The developed light-scattering factor of glare sensitivity recorded with a colored luminous target is shown to be a valuable clinical index of lens transparency. After 9 months, the worse and better eyes of older adult drivers and older drivers with cataract treated with 1% NAC generally showed an improvement of visual functions as compared with baseline. The results of glare testing shows a reduction of light scattering in the worse and better eyes of older drivers. Glare sensitivity improvement was accompanied by improvement in visual acuity more pronounced in the eyes with cataract during treatment with NAC. The data of visual functions (visual acuity, glare sensitivity) in older adult subjects and older subjects with cataract treated with 1% NAC showed significant improvement as compared, by contrast with the control group which showed generally no improvement in visual functions, with no difference from baseline in visual acuity and glare sensitivity readings. In most of the patients treated, study treatment was well tolerated and no ocular or systemic adverse events were reported. Use of NAC to treat cataract and aging lens can lead to diminishing of light scattering units in the lens which raise glare effect, probably by prevention of the oxidative modification of crystallins and utilization of lipid peroxides.[@b42-cia-4-031]

NAC acts as a universal antioxidant both in the lipid phase of the cellular lens membranes and in their aqueous environment and protects the crystalline lens from oxidative stress-induced damage.[@b3-cia-4-031]

Conclusion
==========

The results of this study provide a substantial basis for further evaluation of NAC in the treatment and prevention of visual impairment in the temporal cross-sections of an older population several years apart. This ophthalmic drug showed potential for the nonsurgical treatment of age-related cataracts for participants after controlling for age, gender and daily activities and on a combined basis of repurchases behavior reports in various significant cohort survivors, now has been demonstrated to have a high efficacy and good tolerability for prevention and treatment of visual impairment determined for the older population with relative stable pattern of causes for blindness and visual impairment.

This work was planned, organized, and supported by Innovative Vision Products, Inc. (IVP; County of New Castle, DE, USA). IVP is a holder of the worldwide patent (including PCT International Publication Number WO 2004/028536 A1) for the application of *N*-acetylcarnosine for the treatment of ophthalmic disorders, including cataracts. IVP is a pharmaceutical and nanotechnology development company with a direct practical focus on a clinical research in the fields of ophthalmology, research and development of innovative chemical entities, drug-delivery systems, and unique medical devices to target specific biomedical applications. Over the last decade IVP has developed a track record in developing these technologies to effectively address the unmet needs of specific diseased populations.

Or what is necessary to bring the solution up to a pH of ∼6.3--6.8.

![Disability glare results when a light source reflects from or otherwise covers the visual task, like a veil, obscuring the visual target, reducing its contrast and making the viewer less able to see and discriminate what is being viewed. **A.** This drawing illustrates the problem. In this example, bright light from a ceiling/window light fixture or skylight is reflected from the visual task surface, and into the observer's eyes, veiling his recognition of the target visual content. Nearly as much light is reflected from the white paper as from the black ink making the letters, so that the contrast is low and the text is washed out and difficult to read. Such glare "disables" the process of reading. **B.** The example of outdoor glare.](cia-4-031f1){#f1-cia-4-031}

###### 

**A** Halometer DG (face and rear) projection 1, device base; 2, support bar; 3, feed source; 4, block unit for glare testing as seen by subject; 5, rheostat to regulate source brightness; 6, button to turn on/off the voltage feed; 7, clamp; 8, glare source window; 9, moveable optotypes (target); 10, mechanical mechanism for moving the optotypes to/from the glare source; 11, voltage feed plug; 12, a button for choosing among different optotypes, operator side; 13, electronic display of shifted optotype position, operator side; 14, metric scale of optotype distance from glare source, operator side; 15, metric distance scale of the optotype distance from glare source, operator side. **B.** Principle of the disability glare test, based on the measurement of the glare radius (r, mm) a new metric for glare sensitivity. I~0~ = Indicatrix of light scatter; ϕ = angle. The technique utilizes a self-illuminating red or green optotype target and tangential 2 mm 'point light source' seen from a distance of 30 cm. The patient's task is to move the optotype closer to the glare source until it disappears due to the veiling glare from the glare source. A halometer score is determined as follows. The illuminous (in red or green) target is approached from the source so that the patient becomes unable to distinguish the target from the source and then, the target is slowly taken away until the exact moment when the patient distinguishes the target; at this time, the incident light angle ϕ between the source and the target is measured. The target is always fixated with the foveal vision. The target and the 'point light source' are viewed in the same vertical plane, tangential to the plane of emitted light. In this case, to measure the angle ϕ of the incident light between the source and the target, it is necessary only to measure its projection on this vertical plane, which means to measure the distance between the source and the target. The measured glare radius is defined as a target image projection for the vector of light scatter (indicator of light scatter I = I~0~cos ^2^ ϕ) when the glare source is activated and the patient is asked to recognize the target during illumination of the eye with a glare source. **C**. Photograph of working prototype of the Halometer DG tester. Halometer DG instrument can provide the valuable data on the intraocular light scatter in cataracts. The instrument can be used in the pre-testing examination room of optometrist and ophthalmologists offices, at Department of Motor Vehicle licensure facilities or incorporated within automobiles, for self testing. **D**. Vision problems during computer use. The eyes find it difficult to focus on the pixel characters. They can focus on the plane of the computer screen, but cannot sustain that focus. The eyes focus on the screen and relax to a point behind the screen, which is called the resting point of accommodation (RPA) or dark focus. The RPA is different for every individual, but for almost everyone, it is further away than the working distance to the computer. The working distance is the distance from the computer user's eyes to the front of the screen. Therefore the eyes are constantly relaxing to the RPA, and then straining to refocus on the screen. This constant flexing of the focusing (ciliary body) muscles is what creates fatigue, and generates burning and tired eyes. In clinical studies, it has been found that there is a significant difference in the glasses prescription required for focusing on a standard printed near card (called a Snellen card) and focusing on the image of a typical computer screen, both at a viewing distance of 20 inches. Many patients needed a different correction in each eye. **E**. As light passes through the cataractous lens, it is diffused or scattered. The result is blurred or defocused vision.

![](cia-4-031f2a)

![](cia-4-031f2b)

![Can-C^™^ *N*-acetylcarnosine lubricant eye drops developed, manufactured at the cGMP manufacturing facility and worldwide patented by Innovative Vision Products, Inc, Formulation.[@b21-cia-4-031]--[@b23-cia-4-031] The composition is in the form of isotonic solution. Because the composition is applied to the eye, the composition is sterile. The isotonicity of ophthalmic preparation was measured and adjusted as calculated correctly by addition of small concentrations of sodium chloride. The specification of the unique nonracemized natural ([l]{.smallcaps})-isomer form of *N*-acetylcarnosine (see 3D structural formula) recipient included in the Can-C^™^ is presented in [Table 1](#t1-cia-4-031){ref-type="table"}.](cia-4-031f3){#f3-cia-4-031}

![The pictures show the treatment of human cataract in the older subject with the eye drops of 1% Can-C^™^ for the period of 5 months. The left image shows the appearance of cataract which resembles a bat in its form and the right image shows that this opacity has disappeared after the cited period after treatment with n-acetylcarnosine is completed. The lens has become clearer.](cia-4-031f4){#f4-cia-4-031}

![Home health care service. The doctors are often committed to improving a vision healthcare and quality of life of a patient by providing access to the *N*-acetylcarnosine lubricant eye drops (Can-C^™^). To ensure the perfect plan of care, the distributor of eye drops will communicate frequently with the primary physician and with family members if a patient so desires. For insurance coverage, a doctor will write an order for home health nursing.](cia-4-031f5){#f5-cia-4-031}

###### 

Specification of cGMP manufactured *N*-acetyl-[l]{.smallcaps}-carnosine used in IVP drug Can-C^™^ development and clinical studies

  -------------------------------------------------------------------------
  **No**   **Test name**         **Specification**
  -------- --------------------- ------------------------------------------
  1        Appearance            White powder

  2        Identification        Positive

  3        Optical rotation      \[α\][@b20-cia-4-031]~D~ + 25.2°− +27.5°

  4        pH                    4.5--5.5

  5        Heavy metals          NMT 10 ppm

  6        Related substances    [l]{.smallcaps}-carnosine: NMT 0.3%\
                                 Others: NMT 0.2%

  7        Residual solvent      2-propanol: NMT 500 ppm

  8        Water                 NMT 5.0%

  9        Residue on ignition   NMT 0.10%

  10       Assay                 NLT 99.5% (HPLC area)
  -------------------------------------------------------------------------

**Abbreviations:** NMT, not more than; NLT, not less than.

###### 

Computer user questionnaire Do you notice any of these visual symptoms? Please rate the following symptoms by underlining the appropriate description

  **Symptom**                                                   **Severity**              
  ------------------------------------------------------------- -------------- ---------- --------
  Headaches during or after working at the computer             Mild           Moderate   Severe
  Overall bodily fatigue or tiredness                           Mild           Moderate   Severe
  Burning eyes                                                  Mild           Moderate   Severe
  Distance vision is blurry when looking up from the computer   Mild           Moderate   Severe
  Dry, tired, or sore eyes                                      Mild           Moderate   Severe
  Squinting helps when looking at the computer                  Mild           Moderate   Severe
  Neck, shoulder, or back pain                                  Mild           Moderate   Severe
  Double vision                                                 Mild           Moderate   Severe
  Letters on the screen run together                            Mild           Moderate   Severe
  Driving/night vision is worse after computer use              Mild           Moderate   Severe
  "Halos" appear around objects on the screen                   Mild           Moderate   Severe
  Need to interrupt work frequently to rest eyes                Mild           Moderate   Severe

###### 

Demographic and ergonomic occupational characteristics of cataract and no cataract adult subjects enrolled in the study

                                                                          **Cataract**   **No cataract**              
  ----------------------------------------------------------------------- -------------- ----------------- ---------- -----
  Total                                                                   75                               72         
  Age groups                                                                                                          
  50--59 years                                                            18             24                18         25
  60--69 years                                                            43             57                40         56
  70--85 years                                                            14             19                14         19
  Sex                                                                                                                 
  Female                                                                  36             48                38         53
  Male                                                                    39             52                34         48
  Race                                                                    White 75       100               White 72   100
  Driving exposure[\*](#tfn3-cia-4-031){ref-type="table-fn"}                                                          
  Total                                                                   40             53                42         58
  \<150 km/wk                                                             23             58                17         41
  \>= 150 km/wk                                                           17             42                25         59
  **Computer users**                                                                                                  
  Total                                                                   47             63                51         71
  Occasional computer users[\*\*](#tfn6-cia-4-031){ref-type="table-fn"}   17             36                21         41
  Moderate computer users[\*\*](#tfn6-cia-4-031){ref-type="table-fn"}     18             38                16         31
  Intensive computer users[\*\*](#tfn6-cia-4-031){ref-type="table-fn"}    12             26                14         28

**Notes:** Data are presented as numbers and percentages.

Driving subjects were classified into 2 categories according to whether they drove more or less than the median number of km (150 km) driven per week based on the distribution of all subjects. Although this was a self-report measure, prior studies indicate that older adults can provide valid estimates of driving exposure \[[@b18-cia-4-031], [@b24-cia-4-031]\].

Occasional computer user: This individual typically uses the computer for less than 3 hours per day. This user tends to have an extensive variety of different tasks (computer and other) and they are unlikely to regularly spend extended amounts of time sitting and working at the computer.

Moderate computer user: This individual typically uses the computer between 3--5 hours per day. This user tends to have some variety in the daily work tasks but they regularly may spend up to half the workday at the computer.

Intensive computer user: This individual typically spends more than 5 hours per day on the computer. This user may have a limited number of noncomputer-related tasks or none at all. These individuals are considered to be at high risk of developing computer-related injuries if precautions such as appropriate workstation design, layout and work practices are not addressed.

###### 

Distribution of visual acuity and disability glare in the cataract and noncataract groups of the adult subjects enrolled in the study at baseline examination

                                             **Adult subjects**             
  ------------------------------------------ -------------------- ---- ---- ----
  Total                                      75                        72   
  Worse eye                                                                 
  **Visual acuity**                                                         
  20/25 or better                            9                    12   50   70
  20/25 to 20/30                             14                   19   13   18
  20/35 to 20/50                             48                   64   6    8
  Worse than 20/50                           4                    5    3    4
  Disability glare readings (glare radius)                                  
  At red target                                                             
  \<12 mm                                    10                   14   27   38
  ≥12 mm                                     65                   86   45   62
  At green target                                                           
  \<12 mm                                    7                    9    20   28
  ≥12 mm                                     68                   91   52   72
  Better eye                                                                
  **Visual acuity**                                                         
  20/25 or better                            12                   16   53   74
  20/25 to 20/30                             30                   40   9    12
  20/35 to 20/50                             25                   34   7    10
  Worse than 20/50                           8                    10   3    4
  Disability glare readings (glare radius)                                  
  At red target                                                             
  \<12 mm                                    29                   38   40   55
  ≥12 mm                                     46                   62   32   45
  At green target                                                           
  \<12 mm                                    18                   24   24   34
  ≥12 mm                                     57                   76   48   66

**Notes:** Normal measures of glare sensitivity of young subjects (20--30 years) with best correction without cataracts are 3 ± 2 mm (mean SD) of at least four measurements at red and green targets in the daytime.[@b12-cia-4-031]

###### 

Linear correlation coefficients (R) between the characteristics of older subjects with cataract and noncataract older adult subjects measured by visual acuities (VA) and glare radius (GR at red and green targets) at baseline and at 9-month follow-up ophthalmic examinations

                                                                                **Baseline study**   **9 months**                                                                                                    
  ----------------------------------------------------------------------------- -------------------- ------------------------------------------------- ------------------------------------------------- --- ------- -------------------------------------------------
  Older subjects with cataract[+](#tfn8-cia-4-031){ref-type="table-fn"}                                                                                                                                              
  VA                                                                            X                    −0.63[\*](#tfn9-cia-4-031){ref-type="table-fn"}   −0.65[\*](#tfn9-cia-4-031){ref-type="table-fn"}   X   −0.47   −0.45
  GR red target                                                                                      X                                                 +0.83[\*](#tfn9-cia-4-031){ref-type="table-fn"}       X       +0.94[\*](#tfn9-cia-4-031){ref-type="table-fn"}
  GR green target                                                                                                                                      X                                                             X
  Older adult no-cataract subjects[++](#tfn10-cia-4-031){ref-type="table-fn"}                                                                                                                                        
  VA                                                                            X                    −0.61[\*](#tfn9-cia-4-031){ref-type="table-fn"}   −0.66[\*](#tfn9-cia-4-031){ref-type="table-fn"}   X   −0.43   −0.46
  GR red target                                                                                      X                                                 +0.81[\*](#tfn9-cia-4-031){ref-type="table-fn"}       X       +0.91[\*](#tfn9-cia-4-031){ref-type="table-fn"}
  GR green target                                                                                                                                      X                                                             X

**Notes:** ^+^Number of eyes examined 75;

p \< 0.01;

^++^Number of eyes examined 72.

###### 

Visual function in the better and worse eyes after 9 months of treatment with *N*-acetylcarnosine 1% eye drops (Can-C^™^) versus baseline examination

                                                                          **Adult subjects**             
  ----------------------------------------------------------------------- -------------------- ---- ---- ----
  Total                                                                   39                        37   
  Baseline examination                                                                                   
  **Worse eye**                                                                                          
  Visual acuity                                                                                          
  20/25 or better                                                         5                    13   26   70
  20/25--20/30                                                            8                    21   5    14
  20/35--20/50                                                            22                   56   3    8
  Worse than 20/50                                                        4                    10   3    8
  Disability glare readings (glare radius)                                                               
  At red target                                                                                          
  \<12 mm                                                                 6                    15   15   41
  ≥12 mm                                                                  33                   85   22   59
  At green target                                                                                        
  \< 12 mm                                                                4                    10   11   30
  ≥12 mm                                                                  35                   90   26   70
  **Better eye**                                                                                         
  Visual acuity                                                                                          
  20/25 or better                                                         5                    13   25   68
  20/25--20/30                                                            12                   31   8    22
  20/35--20/50                                                            17                   43   2    5
  Worse than 20/50                                                        5                    13   2    5
  Disability glare readings (glare radius)                                                               
  At red target                                                                                          
  \<12 mm                                                                 10                   26   21   57
  ≥12 mm                                                                  29                   74   16   43
  At green target                                                                                        
  \<12 mm                                                                 8                    21   12   32
  ≥12 mm                                                                  31                   79   25   68
  **After 9 months of treatment with *N*-acetylcarnosine 1% eye drops**                                  
  **Worse eye**                                                                                          
  Visual acuity                                                                                          
  20/25 or better                                                         9                    23   27   73
  20/25--20/30                                                            16                   41   7    19
  20/35--20/50                                                            13                   33   2    5
  Worse than 20/50                                                        1                    3    1    3
  Disability glare readings (glare radius)                                                               
  At red target                                                                                          
  \<12 mm                                                                 12                   30   25   67
  ≥12 mm                                                                  27                   70   12   33
  At green target                                                                                        
  \<12 mm                                                                 10                   25   21   56
  ≥12 mm                                                                  29                   75   16   44
  **Better eye**                                                                                         
  Visual acuity                                                                                          
  20/25 or better                                                         15                   38   30   80
  20/25--20/30                                                            18                   47   5    14
  20/35--20/50                                                            4                    10   1    3
  Worse than 20/50                                                        2                    5    1    3
  Disability glare readings (glare radius)                                                               
  At red target                                                                                          
  \<12 mm                                                                 18                   45   30   81
  ≥12 mm                                                                  21                   55   7    19
  At green target                                                                                        
  \<12 mm                                                                 19                   46   21   57
  ≥12 mm                                                                  21                   54   16   43

###### 

Visual function in the better and worse eyes after 9 months of treatment with placebo (Control group) versus baseline examination

                                                 **Adult subjects**             
  ---------------------------------------------- -------------------- ---- ---- ----
  Total                                          36                        35   
  Baseline examination                                                          
  **Worse eye**                                                                 
  Visual acuity                                                                 
  20/25 or better                                3                    8    21   60
  20/25--20/30                                   7                    19   7    20
  20/35--20/50                                   23                   64   5    14
  Worse than 20/50                               3                    8    2    6
  Disability glare readings (glare radius)                                      
  At red target                                                                 
  \<12 mm                                        9                    25   17   49
  ≥12 mm                                         27                   75   18   51
  At green target                                                               
  \<12 mm                                        6                    17   11   31
  ≥12 mm                                         30                   83   24   69
  **Better eye**                                                                
  Visual acuity                                                                 
  20/25 or better                                11                   31   25   72
  20/25--20/30                                   17                   47   5    14
  20/35--20/50                                   6                    17   5    14
  Worse than 20/50                               2                    5    0    0
  Disability glare readings (glare radius)                                      
  At red target                                                                 
  \<12 mm                                        19                   53   23   66
  ≥12 mm                                         17                   47   12   34
  At green target                                                               
  \<12 mm                                        13                   36   16   46
  ≥12 mm                                         23                   64   19   54
  **After 9 months of treatment with placebo**                                  
  **Worse eye**                                                                 
  Visual acuity                                                                 
  20/25 or better                                2                    6    19   54
  20/25--20/30                                   6                    17   9    26
  20/35--20/50                                   25                   69   5    14
  Worse than 20/50                               3                    8    2    6
  Disability glare readings (glare radius)                                      
  At red target                                                                 
  \<12 mm                                        8                    22   16   46
  ≥12 mm                                         28                   78   19   54
  At green target                                                               
  \<12 mm                                        5                    14   8    23
  ≥12 mm                                         31                   86   27   77
  **Better eye**                                                                
  Visual acuity                                                                 
  20/25 or better                                9                    25   25   71
  20/25--20/30                                   17                   47   5    14
  20/35--20/50                                   8                    22   5    14
  Worse than 20/50                               2                    6    0    0
  Disability glare readings (glare radius)                                      
  At red target                                                                 
  \<12 mm                                        16                   44   21   60
  ≥12 mm                                         20                   56   14   40
  At green target                                                               
  \<12 mm                                        10                   28   14   40
  ≥12 mm                                         26                   72   21   79

###### 

Mean ± SD of changes (improvement) in visual functions

  **Treatment group**                                     **Visual acuity**                                                                                             **Glare radius**
  ------------------------------------------------------- ------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------
  9-month follow-up of older subjects with cataract                                                                                                                     
  Control group                                           0.90 ± 0.03 (*n* = 36)                                                                                        1.53 ± 0.07 (*n* = 36)
  NAC-treated group                                       1.54 ± 0.05[\*](#tfn12-cia-4-031){ref-type="table-fn"}[+](#tfn13-cia-4-031){ref-type="table-fn"} (*n* = 39)   0.41 ± 0.05[\*](#tfn12-cia-4-031){ref-type="table-fn"} (*n* = 39)
  9-month follow-up of older adult noncataract subjects                                                                                                                 
  Control group                                           0.96 ± 0.03 (*n* = 35)                                                                                        1.27 ± 0.05 (*n* = 35)
  NAC-treated group                                       1.20 ± 0.04[\*](#tfn12-cia-4-031){ref-type="table-fn"} (*n* = 37)                                             0.38 ± 0.05[\*](#tfn12-cia-4-031){ref-type="table-fn"} (*n* = 37)

**Notes:** The measure of visual acuity readings after 9 months of treatment was divided by the clinical baseline measure of visual acuity for each eye individually to get ratios, and then the average of those ratios through each clinical group of eyes was calculated. Similarly with glare, the calculating of the ratio of glare sensitivity at red and green target after 9 months of treatment to the baseline reading of glare sensitivity for each eye was undertaken, and then the ratios were averaged through the whole groups of eyes.

*p* \< 0.001 compared to control group who received placebo eye drops;

*p* \< 0.001, where an improvement of visual acuity is statistically significantly better in the group of older subjects with cataract than an improvement of visual acuity in the group of older adult noncataract subjects.

**Abbreviation:** NAC, *N*-acetylcarnosine (Can-C^™^).

###### 

Can-C^™^ testimonials

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  "I'd like to thank you for researching and developing Can-C**^™^**. During an eye exam, they informed me I had the start of cataracts and would likely need surgery in about 5 yrs. I was 56 and horrified, especially as I am the designated driver for my social unit: me, mom and our diabetic friend who's legally-blind from retinopathy.
    I searched the net and learned about Can-C**^™^**. Calling around to double-check their safety, I was shocked to learn that there was no NIH or other government studies. One researcher I talked to said that as long as there was an effective treatment- meaning surgery, there would be little chance of any studies being done, at least he was honest about the entrenched nature/power of the cataract surgery crowd.
    Anyway, I started the drops 2-drops each eye twice a day, within 3 weeks; there was a significant and dramatic improvement which continued for awhile longer. Now I use 1-drop in each eye daily; 2-drops if I indulge in lots of carbohydrates. Plus the Can-C**^™^** drops are especially soothing when my eyes are tired and gritty feeling."
  *L. P. California*
  "Good news to report! It is too good for words. I have been using the Can-C**^™^** eye drops for a month for cataracts in both eyes. First thing I noticed was that lights seem brighter and have noticed that print is easier to read. I am near-sighted also, so being able to see numbers more clearly on a hymn board across the room is very exciting! I am hoping for more clarity as I continue to use the drops. This is too good to be true but it really is."
  *C. K. Ireland*
  "I used Can-C**^™^** for 4-months with amazing results. My vision in my left eye improved from 20/40 to 20/25 and upon renewal of my driving license, the eye glass restriction was eliminated! With less glare and near perfect vision I now drive in the evenings and early morning without glasses, much as I did in my youth 30-years ago! Since birth, my right eye could only identify the big "E" on the eye chart. After 4-months of Can-C**^™^** treatment, I can now read the 3rd line on the eye chart. It's truly amazing to be nearly blind in my right eye for 60 years and now regain some sight!"
  *Dr R. L. Hawaii*
  "For several years I have suffered from uveitis and macula edema in one eye. The macula edema has settled but the uveitis is only controlled with corticosteroid eye drops. I tried to gradually reduce the corticosteroid drops and replace them with the carnosine, but this was not entirely successful and after a visit to the specialist I am back using the coticosteroid drops. I didn't know whether it would be of any value to use both at the same time. What the carnosine did do was reduce the pressure and as both my parents had glaucoma I am very conscious of the need to keep the pressure down. So I may need to use the carnosine for that in the future and of course I realize that extended use of the steroid drops can cause cataracts."
  *J. K. Australia*
  "Most of my patients are using Can-C^™^ as prevention; but some started it as a cure for the beginning of their cataracts. Keep up the good work."
  *Dr D.K. New York*
  I have used your Can-C^™^ drops for 3 or 4 months and have noticed clearer vision. I stopped using the drops and my vision became fuzzy again. So I restarted the drops about two weeks ago. I will continue to use them and plan to reorder when necessary. The results were good, but know that I need to use them on an ongoing basis."
  *E.K. Utah*
  "I have used Can-C^™^ eye-drops at a rate of approximately 2 drops /day in each eye for 3-months. I was suffering from brunescent cataracts and unrecognized night blindness in both eyes, I can report these results in that time."
  1\. My night vision has returned, and I again feel safe driving at night. The halo around bright lights is very much diminished; some small "sparkles" remain, but do not present any problem for me.
  2\. I have found no negative side-effects.
  3\. My vision has improved by approximately "2 chart lines" and I can again read highway signs without glasses.
  *R.L. Colorado*
  I have been using Can-C^™^ for about three months now and have noticed an improvement in my vision. Also I am not waking in the mornings with gummed up and watery eyes as was the case previously. I should know more after my next eye examination."
  *J.E. Australia*
  "I have purchased Can-C^™^ for my mother who has senile cataracts. Anecdotal reporting from her after a few months is that she feels she can see better."
  *J.H., Colorado*
  "My ophthalmic physician wants to know what I have been doing! He hasn't seen anything like it before in 20 years of assisting people with cataracts!"
  *K. L. New York*
  "Congratulations, these eye drops are the real McCoy, they're great!"
  *G. K. Washington*
  "I took some eye drops for 4 months that did nothing. I've only been taking Can-C^™^ eye drops for 4-weeks and can already see the difference".
  *A. M. Canada*
  "I can't express the delight I feel at having to avoid surgery, your eye drops have given great hope for the future."
  *M. J. K. Colorado*
  "I just wanted you to know that the improvement in my vision is amazing. I had gotten to the point where I could no longer drive due to haziness from my cataracts, and now I feel very secure and am able to see almost as well as before my cataracts were diagnosed. Also, I have not noticed any kind of side effects. I just wanted to tell you how happy I am and that I am definitely recommending Can-C^™^ eye-drops to all my friends with similar problems! If you need me for any referrals or statistics I would be happy to help! Please keep on with the great work!"
  *A.B. Kansas*
  I have been taking the Can-C^™^ eye-drops since February. I had my vision checked in April and my vision has improved four times and my lens is clearing. I get my vision checked again in July. I will keep you informed of my progress. Can-C^™^ drops have been a godsend to me."
  *B.K. Bermuda*
  I want to tell you about my experiences with the special Russian eye-drops. At first I didn't think there were any real differences, but I persisted in using the drops twice a day in the affected eye. Now after about 3 months I believe that there are significant changes to my vision. It's been a fairly gradual thing which may explain why I didn't appreciate any changes early on, but now it's obvious to me that my eyesight has improved. The changes are slower than I anticipated, but I for one am sold on the drops!"
  *C.B.S. Hong Kong*
  "I have received 4 boxes of Can-C^™^ and only used them for 4 days as I write this at one drop/day in the left eye, my "problem" eye. I felt immediate relief the very first day of using the drops, it was uncanny. Then I thought, maybe it was all mental, that I wanted them to work for me. So at the fourth day it is difficult to tell you how much better the eye feels now. I was having extreme sensitivity to sunlight in the left eye, now it hardly bothers me. The eye had been feeling "swollen" and it was difficult for me to look upward, I had to lower my head back to look up at anything. All this appears to be disappearing. Before I started with the Can-C^™^, I went to see an ophthalmologist. I was given a complete examination for cataracts, macular degeneration and glaucoma, and he saw a slight beginning of a cataract and macular degeneration, the glaucoma was not mentioned. This doctor did absolutely nothing for the actual problem I went in for, simply told me to use a warm, moist compress on that left eye for 15 minutes, twice a day, but it did no good. I worked all my years as a research biochemist for a leading pharmaceutical company, so I am familiar with the medical terms and do know that the acetyl radical does take the carnosine through the membranes. I am very excited about these drops, thank you so much for these drops, you cannot imagine how much my well being has changed since using them, my left eye problem had simply consumed me completely, I found myself snapping and being rude to my closest of friends all because of that most uncomfortable eye problem. Thanks so much."
  *R. S. Alabama*
  "I started using the Can-C^™^ eye drops and found that it started to clear the cataract but stopped. I chose a cheaper brand that was not approved by IVP. This actually has made the cataract worse! Then I read Dr. Babizhayev's statement about the dangers from the imitators- which I have shown to be the case. I shall be back to the Can-C^™^ as soon as possible."
  *P.S. Dubai*
  "I've been using Can-C^™^ for a month and I've noticed an improvement in my vision, particularly less glare, I intend to keep using it and let you know the results."
  *P.M.J. Australia*
  "The Can-C^™^ eye-drops have given improvement to my mother's eyesight over the past 3 weeks. It is certainly amazing."
  *J.C. Texas*
  "Can-C^™^ eye-drops may be one of the most significant advances and developments for aging eyes, especially as they appear to be able to substitute for surgery in many cases."
  *P.M. Great Britain*
  "Can-C^™^ represents a real breakthrough and a genuine example of antiaging medicine at its best."
  *Dr R.M. Switzerland*
  "As a medical doctor, at first I was dubious of such a breakthrough, but I assisted my mother-in-law with the application; the results have been so impressive I am now contacting you with a view to a wholesale enquiry."
  *Dr D.S. California*
  "Wundervoll! I write to tell you that I have many positive results with your Can-C^™^ drops."
  *M.D. Germany*
  "The more regularly I use the eye-drops the more benefit I perceive. I think Can-C^™^ is a real breakthrough for ageing eyes, hopefully they and the information about them will become popular soon; you deserve success with this great product."
  *A.P.M. Great Britain*
  "I would like to relay to you my great satisfaction with the Can-C^™^ cataract drops! I have been administrating the product for approximately 2 ½ months to my 5-year-old Yorkshire terrier who has diabetic induced cataracts. The cataracts were completely opaque and she had no sight in either eye. The left eye is already partially clear of cataract and the right shows signs of clearing. Partial vision has returned. I was considering eye surgery when she was first diagnosed, but with the results I have seen so far I feel it's not warranted. I would highly recommend this product to anyone! Again, thank you for this life saver!"
  *L..C. New Jersey*
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